Back دولوكسيتين Arabic دولوکستین AZB Duloxetin Danish Duloxetin German Ντουλοξετίνη Greek Duloxetina Spanish دولوکستین FA Duloksetiini Finnish Duloxétine French דולוקסטין HE
Duloxetine, sold under the brand name Cymbalta among others,[1] is a medication used to treat major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, fibromyalgia, neuropathic pain and central sensitization.[10][11] It is taken by mouth.[10]
Duloxetine is a serotonin–norepinephrine reuptake inhibitor (SNRI).[12] The precise mechanism for its antidepressant and anxiolytic effects is not known.[10]
Common side effects include dry mouth, nausea, feeling tired, dizziness, agitation, sexual problems, and increased sweating.[10] Severe side effects include an increased risk of suicide, serotonin syndrome, mania, and liver problems.[10] Antidepressant withdrawal syndrome may occur if stopped.[10] There are concerns that use during the later part of pregnancy can harm the developing fetus.[10]
Duloxetine was approved for medical use in the United States[10][13] and the European Union in 2004.[5][7] It is available as a generic medication.[12] In 2022, it was the 31st most commonly prescribed medication in the United States, with more than 18 million prescriptions.[14][15]
- ^ a b "Duloxetine". Drugs.com. Archived from the original on 29 September 2018. Retrieved 24 December 2018.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). 31 March 2023. Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ^ a b Cite error: The named reference
Cymbalta FDA labelwas invoked but never defined (see the help page). - ^ a b "Cymbalta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 20 October 2020. Retrieved 30 September 2020.
- ^ "Cymbalta PI". Union Register of medicinal products. 22 December 2004. Archived from the original on 19 December 2024. Retrieved 19 December 2024.
- ^ a b Cite error: The named reference
Yentreve EPARwas invoked but never defined (see the help page). - ^ "Yentreve PI". Union Register of medicinal products. 13 August 2004. Archived from the original on 19 December 2024. Retrieved 19 December 2024.
- ^ a b Cite error: The named reference
pmid21366359was invoked but never defined (see the help page). - ^ a b c d e f g h "Duloxetine". Monograph. The American Society of Health-System Pharmacists. Archived from the original on 26 November 2018. Retrieved 24 December 2018.
- ^ "Medications for OCD". International OCD Foundation. Archived from the original on 27 January 2024. Retrieved 25 February 2024.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 364–365. ISBN 9780857113382.
- ^ Cite error: The named reference
FDA Cymbalta Approval Packagewas invoked but never defined (see the help page). - ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Duloxetine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Archived from the original on 1 September 2024. Retrieved 30 August 2024.